Table 1.

Completed HIV-1 Vaccine Efficacy Trials

Trial	Vaccine Description	Immune Responses Observed	Efficacy Outcome
Vax004	AIDSVAX B/B gp120 (MN and GNE8 subtype B) gp120 in alum	Non-neutralizing antibody response; ADCVI	No efficacy
Vax003	AIDSVAX B/E gp120 (subtype B MN and CRF01_AE CM244) gp120 in alum	Non-neutralizing antibody response	No efficacy
HVTN 502/STEP Trial	Adenovirus type 5 Clade B gag/pol/nef	HIV-1 specific CD4+ and CD8+ responses	No efficacy, increased infection risk
HVTN 503 (Phambili trial)	Adenovirus type 5 Clade B gag/pol/nef	HIV-1 specific CD4+ and CD8+ responses	No efficacy, increased infection risk
RV144	ALVAC-HIV (recombinant canarypox vector)/vCP1521 and AIDSVAX B/E rgp120 in alum	Humoral and cellular immune responses; Non-neutralizing Ab to V1V2*, high ADCC, HIV-1 specific IgG3, FcγRIIC receptor * Correlate of protection	31.2 % efficacy at 42 months, 60% efficacy at 12 months
HVTN 505	DNA Gag, Pol, and Nef from HIV-1 subtype B and Env from subtypes A, B, and C, and rAd5 subtype B Gag- Pol and Env A, B, and C	T-cell responses to HIV-1 potential T- cell epitopes; CD4+ HIV Gag responses	No efficacy

HVTN, HIV Vaccine Trials Network; ADCVI, antibody-dependent cell-mediated virus inhibition; ADCC, antibody-dependent cellular cytotoxicity